Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels


Alpine Immune Sciences Reports First Patient Dosed In Its ALPN-101 Phase 2 Lupus Trial; Reports $45M Development Milestone Payment


Benzinga | Jun 24, 2021 08:04AM EDT

Alpine Immune Sciences Reports First Patient Dosed In Its ALPN-101 Phase 2 Lupus Trial; Reports $45M Development Milestone Payment






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC